关键词 | DT新叶奖 |道生生物| 合成生物色素：合成生物靛蓝 生物基领域"奥斯卡"——「 2026(第4届)DT新叶奖 」已开启申报，将于第11届生物基大会 暨展览正式揭晓，并举行颁奖典礼。设置 四大奖项： 创新材料奖、创新应用奖、最具商业价 值奖、创新行业解决方案奖。 免费报名截止 3月13日，享独家宣传。 参选单位&独家宣传 ： 万华化学 光华伟业 双枪科技 裕同包装 华润双鹤 利夫生物 中科国生 丰原生物 聚维元创 糖能科技 京博中聚 骐业科技 赛泓环境 河南浩森生物 军安绿色新材 华 呋新材 亚科股份 麒祥新材料 泰安羽时 元一生物 华澄生物 世倍尔 播下环保 凤登绿能 和塑 美 拜科瑞生物 碧嘉材料 霍桐仪器 科幂仪器 无锡华辰 托摩根生物 谱键科技 碧普仪器 道生 生物 德渊集团 普拉斯新材 漂莱特 碳和新材 博辉合生 微谱检测 武汉瑞鸣 树合科技 唯铂莱 生物 合碳创物 深圳职业技术大学 百葵锐 上海滩泰 禾元新材... ... 合成生物色素领导者 —— 道生生物 （深 圳）有限公司 已确认参选 2026(第4届)DT新叶奖 ，以 合成生物色素：合成生物靛蓝 竞选 "创新材料奖 " 。 1 ...

新京报贝壳财经讯（记者阎侠）2月4日，大北农发布公告，公司实际控制人、董事长邵根伙于2026年2 月3日因病逝世，享年60岁。 目前，公司董事会、高级管理人员正常履职，公司各项经营业务正常开展。 公开资料显示，邵根伙于1965年出生，中共党员，中国农业大学农学博士。邵根伙曾任教于北京农学 院。1994年10月，邵根伙创建北京大北农科技集团股份有限公司。 去年9月，2025年大北农集团丰收节开幕之际，邵根伙在现场发表致辞。他说，大北农集团创业32年， 自两个人、两万元、两间房起步，集团以强农报国为使命，以2035年实现全球第一农业科技企业为愿 景。创新是集团的核心，现有2000人的研发团队，拥有国家重点实验室，创立了大北农科技奖，成果多 次获得大奖。 大北农集团微信公众号显示，2026年1月10日至11日，绿色生物制造全国重点实验室2025年学术年会暨 首届绿色生物制造青年科学家论坛在北京大北农凤凰国际创新园举办。邵根伙也参加了这个论坛。他在 开幕致辞中表示，2025年作为实验室起步建设的"元年"，已在科研攻关与成果转化上取得良好开端。他 强调，生物制造是引领变革的"新质生产力"，在全体同仁的努力下必将建设成为 ...

Core Viewpoint - The article highlights the launch of a significant industrial project by Bojiao Biotechnology, focusing on synthetic biology and green manufacturing, with a total investment of 1.275 billion yuan, aiming for production capacity and substantial annual sales revenue [1][3]. Group 1: Project Overview - Bojiao Biotechnology's industrialization and research project is a provincial key industrial initiative with a total investment of 1.275 billion yuan [1]. - The project is expected to complete its core production and supporting facilities from January 2026 to June 2027, with production capacity reaching 156.2 tons of raw materials, 300 million dosage forms, and 15 million bottles annually [1]. - The anticipated annual sales revenue is projected to exceed 5 billion yuan, with annual tax and profit exceeding 500 million yuan [1]. Group 2: Technological Focus - The project is centered around synthetic biology, integrating AI smart manufacturing and green manufacturing concepts, establishing a comprehensive technical system from strain construction to structural modification [1]. - Bojiao Biotechnology has developed four major technology platforms, including molecular biology, enzyme engineering, green chemistry, and drug delivery, positioning itself in the core technology of terpenoid pharmaceuticals [4]. - The company collaborates closely with Jay Keasling, a pioneer in synthetic biology, and his company Demetrix, aiming to develop more efficient and sustainable biosynthetic processes [5].

这一项目实现了从核心技术到产业化落地的多重突破。在技术层面，柏垠生物已完成多项全球领先的重 组贻贝粘蛋白相关专利布局，构建起坚实的技术壁垒，并成为国内首家完成重组贻贝粘蛋白医疗器械原 料备案的企业，牵头制定首个相关团体标准，填补行业空白。在产品转化方面，项目已实现重组贻贝粘 蛋白原料的规模化量产，并进一步延伸至系列化终端产品。2025年3月，公司获得多个以重组贻贝粘蛋 白为核心的医疗器械产品注册证，推出医用凝胶、创面敷料等国内最全系列产品，广泛应用于伤口护 理、黏膜修复等场景，为消费者提供更安全高效的解决方案。在行业影响上，项目改变了依赖自然资源 提取的传统模式，树立"绿色替代传统"标杆。通过绿色生物制造显著降低生产成本，推动高性能生物材 料普惠化，满足更广泛人群的修复需求；同时减少对海洋生态的依赖，契合"双碳"战略，为生物医药产 业的可持续发展提供新范式。 作为合成生物学领域的创新代表，柏垠生物通过重组贻贝粘蛋白绿色生物制造项目，彰显了"BT+IT"技 术融合的巨大潜力。未来，随着技术的持续迭代与产品矩阵的不断丰富，公司将继续以绿色生物制造赋 能更多传统产业，为新质生产力发展注入更多绿色动能，推动中国生物材 ...

Core Viewpoint - The article highlights a significant breakthrough in the biosynthesis of medium-chain fatty acids (MCFAs) by a research team led by Professor Wang Dan from Chongqing University, utilizing engineered Escherichia coli and bamboo waste as a substrate, achieving a production yield of 9.05 g/L in a 5 L fermentation tank [2][5]. Group 1: Research Breakthroughs - The research team constructed an efficient synthesis pathway in E. coli by deleting specific genes to block β-oxidation and enhance the utilization of multiple carbon sources, resulting in an initial MCFA yield of 2.29 g/L [4]. - Further enhancements were made using protein engineering techniques, achieving a yield of 5.83 g/L and the first synthesis of C6 fatty acids [4]. - The introduction of a carbonic anhydrase gene from Anabaena sp. 7120 improved CO₂ conversion efficiency, raising the yield to 6.72 g/L, and subsequent overexpression of a fatty acid regulatory factor led to a final yield of 9.05 g/L [5]. Group 2: Economic and Environmental Impact - The economic analysis indicates that using bamboo waste hydrolysate instead of glucose as a carbon source reduces the production cost of MCFAs by approximately 17% per ton, showcasing both economic and environmental advantages of this biosynthetic route [5]. Group 3: Institutional Background - Chongqing University is a key national research university, actively contributing to regional and industrial development, with significant achievements in research funding and project approvals [7][8]. - The university's chemical engineering and technology programs rank highly globally, reflecting its strong academic capabilities and commitment to innovation in fields like bio-manufacturing [8]. Group 4: Research Team and Leadership - Professor Wang Dan leads the research team, focusing on biosynthesis of chemical products and new materials, with numerous publications in high-impact journals and significant contributions to national research projects [9].

Core Viewpoint - Weihe Biotechnology has completed a seed round of financing, led by QuanHua Life, focusing on life sciences investment [1] Group 1: Financing Details - The funds raised will primarily be used for the development of a research platform, building a research team, and pilot production of core products [1] - The financing aims to accelerate the biomanufacturing of high-value food new materials, providing more sustainable solutions for the health industry [1] Group 2: Company Focus and Goals - Weihe Biotechnology officially established its presence in the Beijing Agricultural Zhongguancun Science Park in October 2025 [1] - The company is focused on constructing and optimizing efficient cell factories, aiming to promote green biomanufacturing of functional proteins and small molecular active substances [1]

Core Viewpoint - The article discusses the advancements in glycosyltransferase engineering for the efficient glycosylation of flavonoids, highlighting the potential applications in health and wellness products, as well as in the fields of agriculture and biomedicine [5][11]. Summary by Sections Glycosylation of Flavonoids - Flavonoids are important plant secondary metabolites with significant biological activities used in disease prevention and treatment [3]. - The glycosylation of flavonoids is catalyzed by plant UDP-glycosyltransferases (UGTs), which is a green and economical method compared to traditional chemical synthesis [3][4]. Research Findings - The study identified a rare glycosyltransferase, UGT75AJ2, capable of catalyzing the glycosylation at C-3' and C-7 hydroxyl positions of flavonoids, leading to the directed synthesis of bioactive flavonoid glycosides [5][6]. - The research demonstrated that glycosylation at these positions enhances antioxidant and blood sugar-lowering activities [4]. Engineering Strategies - A custom FRISM strategy was developed for the rational design of UGTs, resulting in a quadruple mutant (Mut4-1) of UGT75AJ2 with 128 times the catalytic activity of the wild type [7]. - The strategy was also successfully applied to other glycosyltransferases, validating its effectiveness and versatility [7][8]. Implications and Applications - The study provides a new paradigm for enhancing the activity, donor promiscuity, and regioselectivity of plant glycosyltransferases, which is crucial for the biosynthesis of high-value flavonoid glycosides [11]. - This research integrates multiple disciplines, including food science, synthetic biology, artificial intelligence, and pharmacology, contributing to the development of health products with medicinal value [11].

Core Insights - The article discusses the significance of green biomanufacturing in achieving carbon neutrality and sustainable development, highlighting the recognition of key scientists in the field [2][4][5]. Group 1: Green Biomanufacturing Potential - Biomanufacturing is projected to cover 70% of chemical manufacturing products by the end of this century, with an expected economic value of $30 trillion by 2050, although the current industry scale is less than $8 trillion [4][5]. - The concept of third-generation biomanufacturing, which utilizes carbon dioxide as a raw material, is emphasized as a crucial advancement for addressing carbon neutrality [4][5]. Group 2: Challenges and Innovations - Major scientific challenges include efficiently capturing and activating inert carbon dioxide molecules, requiring the design of new enzyme catalysts and light-enzyme coupling systems [5][6]. - Engineering challenges involve scaling up efficient but fragile biological systems to create stable, continuous, and low-cost reactors, transitioning from laboratory to industrial applications [5][6]. Group 3: Interdisciplinary Collaboration - Effective interdisciplinary collaboration is essential, necessitating the establishment of project communities, shared platforms, and talent communities to foster innovation across biology, chemistry, materials, and information fields [6][7]. - Educational reforms are needed to cultivate talent capable of leading the next industrial revolution, focusing on interdisciplinary courses and encouraging exploratory research [6][7]. Group 4: Global Position and Cooperation - China is transitioning from a "follower" to a "leader" in the global green technology race, with advantages in applied research, industrialization, and market scale [7]. - The proposed international cooperation model emphasizes open collaboration in basic research, innovation alliances in key technologies, and self-reliance in core competitive areas [7].

Core Viewpoint - The article emphasizes the significance of green bio-manufacturing as a sustainable development frontier, predicting that by the end of this century, bio-manufactured products could cover 70% of chemical manufacturing products, with bio-manufacturing potentially accounting for one-third of global manufacturing by 2050, creating an economic value of $30 trillion [4][5]. Group 1: Green Bio-Manufacturing Potential - The current scale of the bio-manufacturing industry is less than $8 trillion, indicating substantial growth potential in the future [4]. - The third generation of bio-manufacturing, which utilizes carbon dioxide as a raw material, is expected to significantly contribute to carbon neutrality efforts [5]. Group 2: Key Challenges and Innovations - Major scientific challenges include efficiently capturing and activating inert carbon dioxide molecules, requiring the design of new enzyme catalysts and light-enzyme coupling systems [5]. - Engineering challenges involve scaling up efficient but fragile biological systems to create stable, continuous, and low-cost reactors, transitioning from laboratory to industrial scale [5]. Group 3: Interdisciplinary Collaboration - Achieving deep integration across disciplines such as biology, chemistry, materials science, and information technology requires the establishment of project communities, shared platforms, and talent communities [6]. - Educational reforms are necessary to cultivate interdisciplinary talent capable of leading the next industrial revolution, including curriculum changes and new evaluation methods [6]. Group 4: China's Position in Global Green Technology - China is transitioning from a "follower" to a "leader" in the global green technology race, with advantages in applied research, industrialization, and market scale [7]. - The proposed international cooperation model emphasizes open collaboration in basic research, innovation alliances in key technology areas, and self-reliance in core competitive fields [7].

Group 1 - The core point of the article is that Hangzhou Jingou Biotechnology Co., Ltd. has completed a multi-million A round financing led by Jinding Capital, with participation from several other investment institutions [1] - The financing will primarily be used for research and development investments and the construction of production capacity, aiming to accelerate the large-scale production of high-value-added nutritional health and feed additive products [1] - Jingou Biotechnology, established in 2023, focuses on synthetic biology technology applications in essential areas such as human nutrition and feed additives, with the goal of creating a leading domestic and internationally competitive green biotechnology manufacturing platform [1] Group 2 - The actual controller of Jingou Biotechnology is Wang Zhimin, who holds a total of 55.24% of the shares and serves as the chairman and general manager of the company [3]